1.95
-0.075(-3.70%)
Currency In USD
| Previous Close | 2.03 |
| Open | 2.02 |
| Day High | 2.02 |
| Day Low | 1.92 |
| 52-Week High | 3.19 |
| 52-Week Low | 0.89 |
| Volume | 49,968 |
| Average Volume | 278,431 |
| Market Cap | 57.38M |
| PE | -2.19 |
| EPS | -0.89 |
| Moving Average 50 Days | 1.96 |
| Moving Average 200 Days | 1.86 |
| Change | -0.08 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $159.84 as of May 09, 2025 at a share price of $1.95. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $627.01 as of May 09, 2025 at a share price of $1.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
GlobeNewswire Inc.
May 01, 2025 11:30 AM GMT
BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ther
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GlobeNewswire Inc.
Apr 30, 2025 11:45 AM GMT
BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule th
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
GlobeNewswire Inc.
Apr 10, 2025 11:00 AM GMT
GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety, tolerability, pharmacokinetic
Data not available